Part D Provisions Sec. 131. Transitional coverage and retroactive Medicare part D coverage for certain low-income beneficiaries. Sec. 132. Allowing the offering of additional prescription drug plans under Medicare part D. Sec. 133. Allowing certain enrollees of prescription drugs plans and MA–PD plans under Medicare program to spread out cost-sharing under certain circumstances. Sec. 134. Establishing a monthly cap on beneficiary incurred costs for insulin products and supplies under a prescription drug plan or MA–PD plan. Sec. 135. Growth rate of Medicare part D out-of-pocket cost threshold. Subtitle E—MedPAC Sec. 141. Providing the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information. Title II—Medicaid Sec. 201. Sunset of limit on maximum rebate amount for single source drugs and innovator multiple source drugs. Sec. 202. Medicaid pharmacy and therapeutics committee improvements. Sec. 203. GAO report on conflicts of interest in State Medicaid program drug use review boards and pharmacy and therapeutics (P&T) committees. Sec. 204. Ensuring the accuracy of manufacturer price and drug product information under the Medicaid drug rebate program. Sec. 205. Improving transparency and preventing the use of abusive spread pricing and related practices in Medicaid. Sec. 206. T–MSIS drug data analytics reports. Sec. 207. Risk-sharing value-based payment agreements for covered outpatient drugs under Medicaid. Sec. 208. Applying Medicaid drug rebate requirement to drugs provided as part of outpatient hospital services. Title III—Food and Drug Administration Subtitle A—CREATES Act Sec. 301. Actions for delays of generic drugs and biosimilar biological products. Sec. 302. REMS approval process for subsequent filers. Sec. 303. Rule of construction. Subtitle B—Pay-for-Delay Sec. 311. Unlawful agreements. Sec. 312. Notice and certification of agreements. Sec. 313. Forfeiture of 180-day exclusivity period.